Matches in SemOpenAlex for { <https://semopenalex.org/work/W3158693330> ?p ?o ?g. }
- W3158693330 endingPage "e564" @default.
- W3158693330 startingPage "e564" @default.
- W3158693330 abstract "Ibrutinib is a covalently binding inhibitor of the B-cell receptor signaling-mediator Bruton’s tyrosine kinase (BTK) with great efficacy in chronic lymphocytic leukemia (CLL). Common side effects like atrial fibrillation (AF), bleeding and infections might be caused by ibrutinib’s inhibition of other kinases in non-B cells. Five-year follow-up of plasma biomarkers by proximity extension assay and immune cell numbers by flow cytometry during ibrutinib treatment revealed that 86 of the 265 investigated plasma biomarkers significantly changed during treatment, 74 of which decreased. Among the 12 markers that increased, 6 are associated with cardiovascular diseases and therefore potentially involved in ibrutinib-induced AF. Comparison between healthy donors and X-linked agammaglobulinemia (XLA) patients, who have nonfunctional BTK and essentially lack B cells, showed indicative changes in 53 of the 265 biomarkers while none differed significantly. Hence, neither B cells nor BTK-dependent pathways in other cells seem to influence the levels of the studied plasma biomarkers in healthy donors. Regarding immune cells, the absolute number of T cells, including subsets, decreased, paralleling the decreasing tumor burden. T helper 1 (Th1) cell numbers dropped strongly, while Th2 cells remained relatively stable, causing Th2-skewing. Thus, long-term ibrutinib treatment has a profound impact on the plasma proteome and immune cells in patients with CLL." @default.
- W3158693330 created "2021-05-10" @default.
- W3158693330 creator A5009217263 @default.
- W3158693330 creator A5031350386 @default.
- W3158693330 creator A5036357426 @default.
- W3158693330 creator A5042513567 @default.
- W3158693330 creator A5051993163 @default.
- W3158693330 creator A5055162775 @default.
- W3158693330 creator A5056740658 @default.
- W3158693330 creator A5067890737 @default.
- W3158693330 creator A5070030873 @default.
- W3158693330 creator A5085322466 @default.
- W3158693330 date "2021-04-26" @default.
- W3158693330 modified "2023-10-07" @default.
- W3158693330 title "Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia" @default.
- W3158693330 cites W1585327912 @default.
- W3158693330 cites W1830209188 @default.
- W3158693330 cites W1891620832 @default.
- W3158693330 cites W1968793561 @default.
- W3158693330 cites W1974559199 @default.
- W3158693330 cites W1974631564 @default.
- W3158693330 cites W1992348202 @default.
- W3158693330 cites W1999504973 @default.
- W3158693330 cites W2001968947 @default.
- W3158693330 cites W2002844028 @default.
- W3158693330 cites W2007989469 @default.
- W3158693330 cites W2010084870 @default.
- W3158693330 cites W2019216438 @default.
- W3158693330 cites W2046304104 @default.
- W3158693330 cites W2057660182 @default.
- W3158693330 cites W2065338378 @default.
- W3158693330 cites W2076995832 @default.
- W3158693330 cites W2085653402 @default.
- W3158693330 cites W2089103836 @default.
- W3158693330 cites W2097191776 @default.
- W3158693330 cites W2100034730 @default.
- W3158693330 cites W2101091483 @default.
- W3158693330 cites W2101996346 @default.
- W3158693330 cites W2113764179 @default.
- W3158693330 cites W2118452964 @default.
- W3158693330 cites W2131823788 @default.
- W3158693330 cites W2131826846 @default.
- W3158693330 cites W2134730637 @default.
- W3158693330 cites W2135215267 @default.
- W3158693330 cites W2147009576 @default.
- W3158693330 cites W2152242507 @default.
- W3158693330 cites W2154360891 @default.
- W3158693330 cites W2163690533 @default.
- W3158693330 cites W2172718055 @default.
- W3158693330 cites W2195033221 @default.
- W3158693330 cites W2276096997 @default.
- W3158693330 cites W2336538042 @default.
- W3158693330 cites W2546767205 @default.
- W3158693330 cites W2559115935 @default.
- W3158693330 cites W2560661681 @default.
- W3158693330 cites W2564504700 @default.
- W3158693330 cites W2580312756 @default.
- W3158693330 cites W2583845930 @default.
- W3158693330 cites W2596464851 @default.
- W3158693330 cites W2730462468 @default.
- W3158693330 cites W2734526350 @default.
- W3158693330 cites W2739932646 @default.
- W3158693330 cites W2745602859 @default.
- W3158693330 cites W2763953131 @default.
- W3158693330 cites W2766430647 @default.
- W3158693330 cites W2790071528 @default.
- W3158693330 cites W2790385276 @default.
- W3158693330 cites W2790498014 @default.
- W3158693330 cites W2795312312 @default.
- W3158693330 cites W2886452066 @default.
- W3158693330 cites W2888425090 @default.
- W3158693330 cites W2910737182 @default.
- W3158693330 cites W2912052125 @default.
- W3158693330 cites W2913122487 @default.
- W3158693330 cites W2925151760 @default.
- W3158693330 cites W2976280418 @default.
- W3158693330 cites W2978680420 @default.
- W3158693330 cites W2983879864 @default.
- W3158693330 cites W2995447457 @default.
- W3158693330 cites W2996045117 @default.
- W3158693330 cites W3010692769 @default.
- W3158693330 cites W3030299620 @default.
- W3158693330 cites W3034924466 @default.
- W3158693330 cites W4250894669 @default.
- W3158693330 doi "https://doi.org/10.1097/hs9.0000000000000564" @default.
- W3158693330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8078281" @default.
- W3158693330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33912812" @default.
- W3158693330 hasPublicationYear "2021" @default.
- W3158693330 type Work @default.
- W3158693330 sameAs 3158693330 @default.
- W3158693330 citedByCount "14" @default.
- W3158693330 countsByYear W31586933302021 @default.
- W3158693330 countsByYear W31586933302022 @default.
- W3158693330 countsByYear W31586933302023 @default.
- W3158693330 crossrefType "journal-article" @default.
- W3158693330 hasAuthorship W3158693330A5009217263 @default.
- W3158693330 hasAuthorship W3158693330A5031350386 @default.
- W3158693330 hasAuthorship W3158693330A5036357426 @default.